Showing results (41-50 of 79) with videos related to
Sort By:
Pageof 8
Clinical Drug Investigation|March 1, 2026
Missed Opportunities in the Therapeutic Patterns of Chronic Obstructive Pulmonary Disease: A Real-World Italian Study on the Impact of Severe Exacerbation on Mortality and Hospital Re-admissionGiulia Ronconi, Letizia Dondi, Leonardo Dondi, et al.Expert Review of Respiratory Medicine|October 9, 2019
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of responseMarco Caminati, Luca Cegolon, Andrea Vianello, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 24, 2021
Exercise prehabilitation in lung cancer: Getting stronger to recover fasterAlice Avancini, Alessandro Cavallo, Ilaria Trestini, et al.Multidisciplinary Respiratory Medicine|February 21, 2015
Health and social impacts of COPD and the problem of under-diagnosisStefano Carlone, Bruno Balbi, Michela Bezzi, et al.Advances in Therapy|May 27, 2021
The Burden of Short-Acting β<sub>2</sub>-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA ProgramFabiano Di Marco, Mariella D'Amato, Francesco P Lombardo, et al.Pulmonary Pharmacology & Therapeutics|February 11, 2014
Omalizumab management beyond clinical trials: the added value of a network modelMarco Caminati, Gianenrico Senna, Fulvia Chieco Bianchi, et al.Respiration; International Review of Thoracic Diseases|March 9, 2025
Vaccination Strategies in Respiratory Diseases: Recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS, and SItIClaudio Micheletto, Stefano Aliberti, Massimo Andreoni, et al.The Journal of Infection|February 12, 2022
Determinants of persistence of symptoms and impact on physical and mental wellbeing in Long COVID: A prospective cohort studyElda Righi, Massimo Mirandola, Fulvia Mazzaferri, et al.Clinical and Translational Allergy|March 16, 2017
Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 monthsAnna Maria Riccio, Pierluigi Mauri, Laura De Ferrari, et al.Journal of Asthma and Allergy|May 19, 2021
Overcoming Barriers to the Effective Management of Severe Asthma in ItalyPierluigi Paggiaro, Simona Barbaglia, Stefano Centanni, et al.Pageof 8